Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine

      This paper is only available as a PDF. To read, Please Download here.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Creese I
        • Feinberg AP
        • Snyder SH
        Butyrphenone influence on the opiate receptor.
        Eur J Pharmacol. 1976; 36: 231-235
        • Opler LA
        • Feinberg SS
        The role of pimozide in clinical psychiatry: A review.
        J Clin Psychiatry. 1991; 52: 221-233
        • Pinder RM
        • Brogden RN
        • Sawyer PR
        • Speight TM
        • Spencer R
        • Avery GS
        Pimozide: A review of its pharmacological properties and therapeutic uses in psychiatry.
        Drugs. 1976; 12: 1-40
        • Roth RH
        Dopamine autoreceptors: Pharmacology, function and comparison with post-synaptic dopamine receptors.
        Communications Psychopharmacol. 1979; 3: 429-433
        • Tecott LH
        • Kwong LL
        • Uhr S
        • Peroutka S
        Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine and pimozide.
        Biol Psychiatry. 1986; 21: 1114-1122
        • Tueth MJ
        • Cheong JA
        Clinical uses of pimozide.
        South Med J. 1993; 86: 344-349